Eidos Therapeutics

SAN FRANCISCO, CA · Founded 2013 · CIK 0001731831 · Biotech · Acquired

Acoramidis, a transthyretin stabilizer molecule for treating ATTR amyloidosis

eidostx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$26M
1 Form D · Apr 2018
102 months since last filing
Contracts
—
No federal contracts on record
Patents
29
8 granted · 21 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$26,047,857
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2457LIFESPLICE PHARMA, LLC——
2458ImmusanT, Inc.—$33M
2459GALECTIN THERAPEUTICS INC—$6.8M
2460Eidos Therapeutics—$26M
2461Expesicor Inc——
2462Actym Therapeutics, Inc.—$25M
2463Verseon Corp—$25M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • ERIC AGUIARDirector
  • JONATHAN FOXExecutive Officer
  • HOYOUNG HUHDirector
  • NEIL KUMARDirector · Executive Officer
  • RAJEEV SHAHDirector
  • UMA SINHAExecutive Officer
  • CHRISTINE SIUExecutive Officer

Patents

USPTO · 8 granted of 29

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.